Evaxion A/S, a leading clinical-level TechBio company, expert in establishing AI-Immunology™-powered vaccines, extended its R&D portfolio with EVX-04, an AI-framed precision cancer vaccine candidate. The company will carry out clinical development of EVX-04, recently been involved in preclinical development, considering it as a new therapeutic vaccine against acute myeloid leukaemia (AML). The EVX-04 is engineered to concentrate on non-conventional ERV (endogenous retrovirus) tumor antigens from the dark genome.
These antigens are seen in tumors, but not present in normal tissue. This makes them the most driven target for cancer vaccines. Accelerating the exclusive AI-Immunology™ platform, Evaxion has addressed ERV antigens in the data recorded for patient tumor sequencing. After that, the platform chooses optimal fragments from these antigens based on their capability to be best best-proven vaccine targets throughout a vast range of patients.
By involving various fragments in EVX-04, the vaccine is engineered to work effectively on every patient with or without tumor and immune ERV antigen differences. This marks EVX-04 as an ‘off-the-shelf’ excellent vaccine preproduced and all set for quick administration after diagnosis.
The CSO and interim CEO of Evaxion, Birgitte Rono, said, “We are very thrilled to choose a popular candidate for our ERV-related precision cancer vaccine concept. This shows a complete, full-fledged novel approach and presents EVX-04 as a great instance of how AI-Immunology™ allow us to establish and design new therapies that will bring the best outcomes for patients. This idea could allow wide use of cancer vaccines involving patients who haven’t responded to conventional immunotherapies.”
Apart from the AI platform the Evaxion’s new preclinical data elaborates EVX-04’s capabilities to eliminate cancer cells and induce powerful T-cell responses. The data will be projected at an oral session to be held on 6th December 2025 at the American Society of Haematology (ASH) Annual Meeting and Exposition in Florida. The presentation will be based on the sessions, such as artificial intelligence, leading tools and techniques in haematology, voiced by the host/presenter Rasmus Villebro, a Bioinformatics Manager at Evaxion.
Birgitte added, “The ASH meeting is the best opportunity for us to highlight our data and present EVX-04 to doctors, potential business partners and both the scientists. We are excited to be chosen to do an oral presentation. Further, we’re looking forward to discussing and sharing the concept and data.”
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
